HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $60 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a 'Buy' rating on Halozyme Therapeutics (NASDAQ:HALO) and maintained a $60 price target.
August 30, 2023 | 10:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Halozyme Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $60.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Halozyme Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100